By adding Canada and the entire Latin America region, including Mexico, WODA completes its full global commercialization offering for rare…
COPENHAGEN, Denmark, January 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™…
8th Sachs Annual Neuroscience Innovation Forum14th Annual LifeSci Advisors Corporate Access EventInvest Securities BioMed Forum 2025MidCap Events Frankfurt 2025Bio-Neuroscience 2025…
Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12 million to $12.3 million, representing 99% growth over…
Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development of VTP-300 in chronic hepatitis…
Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any…
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targets…
LONDON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Pulmocide Ltd., (“the Company”), a late-stage biopharmaceutical company developing inhaled opelconazole for patients…
Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 for wet…
High-volume, breakthrough radioisotope production platform to enable innovation in life sciences and industrial applicationsVALENCIA, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE)…